论文部分内容阅读
[目的]探讨注射用醋酸亮丙瑞林微球联合左炔诺孕酮宫内释放系统治疗子宫腺肌病(AMS)患者的临床疗效.[方法]选取2014年12月至2017年12月在本院72例诊治的AM S患者,按照随机数表法分为观察组和对照组,每组36例.对照组给予左炔诺孕酮宫内释放系统治疗,观察组在对照组基础上加用注射用醋酸亮丙瑞林微球治疗.比较两组疗效及治疗前后子宫体积变化、月经量改变、痛经改善情况、血清癌胚抗原(CA125)水平、生活质量评分和不良反应发生率.[结果]观察组治疗总有效率为94 .44%,显著高于对照组的77 .78%( P ＜0 .05) ;治疗后6个月,观察组子宫体积显著小于对照组,痛经及月经量评分及血清CA125水平显著低于对照组( P ＜0 .05) ,观察组各维度生活质量评分均显著高于对照组( P ＜0 .05) .观察组不良反应发生率为25 .00%,与对照组19 .44% 比较差异无统计学意义( P ＞0 .05) .[结论]左炔诺孕酮宫内释放系统联合注射用醋酸亮丙瑞林微球治疗AMS患者,疗效显著,可显著改善患者临床症状和生活质量,有效降低血清CA125水平,且安全性高,值得临床推广应用.“,”To investigate the clinical effects of leuprolide acetate microspheres combined with levonorgestrel intrauterine delivery system in the treatment of adenomyosis (AM S ).[M ethods]Seventy‐two patients with AM S in our hospital from December 2014 to December 2017 were selected and divided into obser‐vation group and control group according to random number table method ,36 cases in each group .T he control group was treated with levonorgestrel intrauterine release system ,w hile the observation group was treated with leuprorelin acetate microspheres for injection on the basis of the control group .T he curative effect ,uter‐ine volume change ,menstrual volume change ,dysmenorrhea improvement ,serum carcinoembryonic antigen (CA125) ,quality of life score and incidence of adverse reactions were compared between the two groups before and after treatment .[Results]T he total effective rate of the observation group was 94 .44%,which was signifi‐cantly higher than 77 .78% of the control group ( P ＜0 .05).After 6 months of treatment ,the uterine volume of the observation group was significantly smaller than that of the control group ,the dysmenorrhea and men‐strual volume score and serum CA 125 level were significantly lower than those of the control group ( P ＜0 . 05) ,and the quality of life score of the observation group was significantly higher than that of the control group ( P ＜0 .05).T he incidence of adverse reactions in the observation group was 25 .00%,and there was no significant difference between the observation group and the control group (19 .44%) ( P ＞0 .05).[Conclusion]Levonorgestrel intrauterine release system combined with leuprorelin acetate microspheres for injection in the treatment of AM S patients has a significant effect ,can significantly improve the clinical symptoms and quality of life of patients ,effectively reduce the level of serum CA 125 ,and has high safety ,w hich is worthy of clinical application .